At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 149 enrolled
Drug / intervention
CTP-543 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
In Brief
A Phase 2 clinical trial evaluating CTP-543 and CTP-543 matching placebo for Alopecia Areata. Completed, enrolled 149 participants across 13 sites.
Detailed Summary
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartAug 2017
Primary CompletionJul 2019
TodayJul 2026
First PostedMay 2, 2017
Enrollment StartAug 9, 2017
Primary CompletionJul 8, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.2 years ago
Interventions
CTP-543drug
Administered as tablets.
CTP-543 matching placebodrug
Administered as tablets.